Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants

American Journal of Psychiatry

Volumn 160, Issue 8, 2003, Pages 1428-1431

  Gardiner, Sharon J ^a   Kristensen, Judith H ^a   Begg, Evan J ^a   Hackett, L Peter ^a   Wilson, Debbie A ^a   Ilett, Kenneth F ^a   Kohan, Rolland ^a   Rampono, Jonathan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; PIRENZEPINE;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BREAST FEEDING; BREAST MILK; CALCULATION; DRUG BLOOD LEVEL; DRUG MILK LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MILK PRODUCTION; NORMAL HUMAN; NURSING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STEADY STATE; ADULT; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; MALE; METABOLISM;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; BREAST FEEDING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MILK, HUMAN; PIRENZEPINE;

EID: 0041379548     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.8.1428     Document Type: Article

References (27)

1. Zyprexa: Eli Lilly Product Information, in E-MIMS version 4.00.0602. St Leonards, Australia, MediMedia Australia, 2002. http://www.emims.net/login/ about/about_home_fs.htm
2. Stephenson CM, Pilowsky LS: Psychopharmacology of olanzapine: a review. Br J Psychiatry Suppl 1999; 38:52-58
3. Caccia S: Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000; 38:393-114
4. Green B: Focus on olanzapine. Curr Med Res Opin 1999; 15:79-85
5. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
6. Kassahun K, Mattiuz E, Nyhart EJ, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L: Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997; 25:81-93
7. Fulton B, Goa KL: Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53:281-298
8. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37:177-193
9. Kelly DL, Conley RR, Tamminga CA: Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999; 40:101-104
10. Olesen OV, Linnet K: Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of co-medication. Ther Drug Monit 1999; 21:87-90
11. Pritchard DB, Harris B: Aspects of perinatal psychiatric illness. Br J Psychiatry 1996; 169:555-562
12. Brockington IF, Cernik KF, Schofield EM, Downing AR, Francis AF, Keelan C: Puerperal psychosis: phenomena and diagnosis. Arch Gen Psychiatry 1981; 38:829-833
13. Agrawal P, Bhatia MS, Malik SC: Post partum psychosis: a clinical study. Int J Soc Psychiatry 1997; 43:217-222
14. Bhana N, Foster RH, Olney R, Plosker GL: Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61:111-161
15. Yatham LN: The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 2002; 63(suppl 3):10-14
16. Croke S, Buist A, Hackett LP, Ilett KF, Norman T, Burrows GD: Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002; 5:243-247
17. Goldstein DJ, Corbin LA, Fung MC: Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20:399-403
18. Kirchheiner J, Berghöfer A, Bolk-Weischedel D: Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000; 33:78-80
19. Rossiter EJ: The use of developmental screening and assessment instruments by paediatricians in Australia. J Paediatr Child Health 1993; 29:357-359
20. Frankenburg WK, Dodds JB: The Denver Development Screening Test. J Pediatr 1967; 71:181-191
21. Griffiths R: The Abilities of Babies: A Study in Mental Development. Amersham, Bucks, UK, Association for Research in Child and Infant Development, 1976
22. Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF: NCHS Growth Curves for Children: Birth-18 Years: United States. Vital Health Stat 11 1977; 165:1-74
23. Dusci LJ, Hackett LP, Fellows LM, Ilett KF: Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 773:191-197
24. Thomann P: Non-compartmental analysis methods manual, in TopFit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Edited by Heinzel G, Woloszcak R, Thomann P. Stuttgart, Gustav Fischer, 1993, pp 5-66
25. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF: Citalopram and demethylcitalopram in human milk: distribution, excretion and effects in breast-fed infants. Br J Clin Pharmacol 2000; 50:263-268
26. Bennett PN: Use of the monographs on drugs, in Drugs and Human Lactation. Edited by Bennett PN. Amsterdam, Elsevier, 1996, pp 67-74
27. Begg EJ, Atkinson HC, Duffull SB: Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol 1992; 33:501-505